Amarin Corporation plc (AMRN) |
|
1.22 0.03 (2.52%)
|
12-02 16:00 |
|
Open: |
1.16 |
Pre. Close: |
1.19 |
|
High:
|
1.23 |
Low:
|
1.16 |
|
Volume:
|
1,143,157 |
Market Cap:
|
493(M) |
|
|
|
Technical analysis |
as of: 2022-12-02 4:20:52 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 1.49  One year: 1.61 |
| Support: |
Support1: 1.12 Support2: 0.93 |
| Resistance: |
Resistance1: 1.28 Resistance2: 1.37 |
| Pivot: |
1.19  |
| Moving Average: |
MA(5): 1.16 MA(20): 1.21
MA(100): 1.26 MA(250): 2.12 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 26.6 %D(3): 16.3 |
| RSI: |
RSI(14): 52.4 |
| 52-week: |
High: 3.81 Low: 1.03 |
| Average Vol(K): |
3-Month: 2,529 (K) 10-Days: 1,857 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AMRN ] has closed below upper band by 40.2%. Bollinger Bands are 33.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.23 - 1.23 |
1.23 - 1.24 |
|
Low:
|
1.15 - 1.15 |
1.15 - 1.16 |
|
Close:
|
1.21 - 1.22 |
1.22 - 1.23 |
|
Company Description |
|
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland. |
Headline News |
Thu, 01 Dec 2022
Should You Buy Amarin Corporation plc (AMRN) Stock After it Has Gained 0.85% in a Week? - InvestorsObserver
Thu, 24 Nov 2022
BRIEF—Amarin names new head of UK business to lead growth - The Pharma Letter
Mon, 21 Nov 2022
Why Amarin (AMRN) Stock Might be a Great Pick - Nasdaq
Wed, 16 Nov 2022
Amarin Corporation plc (AMRN) Management Presents at 13th Annual Jefferies London Healthcare Conference 2022 (Transcript) - Seeking Alpha
Tue, 15 Nov 2022
Why Amarin Stock Was a Winner Today - The Motley Fool
Wed, 09 Nov 2022
Amarin Co. plc (NASDAQ:AMRN) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
404 (M) |
| Shares Float |
373 (M) |
|
% Held by Insiders
|
1.2 (%) |
|
% Held by Institutions
|
33.3 (%) |
|
Shares Short
|
10,130 (K) |
|
Shares Short P.Month
|
8,830 (K) |
Stock Financials |
|
EPS
|
-0.06 |
|
EPS Est Next Qtl
|
-0.03 |
|
EPS Est This Year
|
-0.21 |
|
EPS Est Next Year
|
-0.06 |
|
Book Value (p.s.)
|
1.46 |
|
Profit Margin (%)
|
-21.8 |
|
Operating Margin (%)
|
-11.6 |
|
Return on Assets (ttm)
|
-3.2 |
|
Return on Equity (ttm)
|
-15 |
|
Qtrly Rev. Growth
|
-36.8 |
|
Gross Profit (p.s.)
|
1.14 |
|
Sales Per Share
|
1.04 |
|
EBITDA (p.s.)
|
-0.12 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-210 (M) |
|
Levered Free Cash Flow
|
27 (M) |
Stock Valuations |
|
PE Ratio
|
-21.79 |
|
PEG Ratio
|
-0.2 |
|
Price to Book value
|
0.83 |
|
Price to Sales
|
1.16 |
|
Price to Cash Flow
|
-2.35 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
